Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abingworth Attracts $375M For Its New Bioventures Fund

Mar 11 2014

• By John Davis

Related Content

In More RNAi Demand, Preclinical Dicerna IPO Piques Investor Interest

Feb 10 2014

Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease

Jan 30 2014

Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch

Dec 02 2013

Gilde’s Latest Venture Fund Guided By Health Care Cost-Cutting

Nov 27 2013

Related Companies

GenSight Biologics S.A.

eFFECTOR Therapeutics, Inc.

Avillion LLP

Avedro, Inc.

Algeta ASA

Bayer AG

Dicerna Pharmaceuticals, Inc.

Ablynx N.V.

Alnylam Pharmaceuticals Inc.

Gilead Sciences, Inc.

Biogen, Inc.

Nightstar Therapeutics plc

Additional Topics

Europe Business Strategies BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window